Pure Global
NCT06103994

Study to Assess the Effect of Multistrain Probiotic on the Immune Response to the Influenza Vaccination

A Randomized, Triple-blinded, Placebo-controlled, Parallel Group Study, to Assess the Effect of Multistrain Probiotic on the Immune Response to the Influenza Vaccination
The Archer-Daniels-Midland Company·ClinicalTrials.gov·dietary supplementRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Influenza
Drug/Device/Intervention
Multistrain probiotic
Study type
Interventional
Intervention type
dietary supplement
Sponsor & location
Primary sponsor
The Archer-Daniels-Midland Company
Location
Athens,, Greece
Timeline & enrollment
Phase
N/A
Start date
Oct 27, 2023
End date
Mar 01, 2024
Enrollment
115 participants
Primary outcome

Change in serum strain-specific geometric mean antibody titers (determined by hemagglutination inhibition [HAI] tests)

Summary

A randomized, triple-blinded, placebo-controlled, parallel group study, to assess the effect
 of multistrain probiotic on the immune response to the Influenza vaccination

ICD-10 classifications
Influenza and pneumoniaInfluenza due to identified seasonal influenza virusInfluenza with other manifestations, seasonal influenza virus identifiedInfluenza with pneumonia, seasonal influenza virus identifiedInfluenza due to identified zoonotic or pandemic influenza virus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06103994
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06103994 through Pure Global AI's free database. This phase not specified trial is sponsored by The Archer-Daniels-Midland Company and is currently Recruiting. The study focuses on Influenza. Target enrollment is 115 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.